Tema Etfs LLC Takes $712,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Tema Etfs LLC bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 7,962 shares of the medical equipment provider's stock, valued at approximately $712,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Lantheus by 47.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock valued at $1,041,000 after purchasing an additional 3,772 shares in the last quarter. Empirical Asset Management LLC acquired a new position in Lantheus during the fourth quarter valued at approximately $323,000. Focus Financial Network Inc. purchased a new stake in Lantheus during the fourth quarter worth approximately $292,000. Janney Montgomery Scott LLC increased its position in shares of Lantheus by 40.9% in the fourth quarter. Janney Montgomery Scott LLC now owns 19,806 shares of the medical equipment provider's stock worth $1,772,000 after acquiring an additional 5,753 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in shares of Lantheus by 31.7% in the 4th quarter. Van ECK Associates Corp now owns 76,996 shares of the medical equipment provider's stock valued at $6,888,000 after acquiring an additional 18,524 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Price Performance

Shares of NASDAQ:LNTH traded down $0.56 during midday trading on Friday, reaching $74.20. The company had a trading volume of 164,232 shares, compared to its average volume of 994,379. The stock has a market capitalization of $5.13 billion, a P/E ratio of 12.35 and a beta of 0.23. The stock's fifty day moving average price is $95.12 and its 200-day moving average price is $92.36. Lantheus Holdings, Inc. has a one year low of $73.11 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same period in the prior year, the firm earned $1.69 EPS. The business's revenue for the quarter was up .8% compared to the same quarter last year. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 in the last three months. 1.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

LNTH has been the topic of several research reports. B. Riley cut their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Truist Financial reduced their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Lantheus has a consensus rating of "Buy" and a consensus price target of $132.67.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.